HealthQuill AstraZeneca
AstraZeneca’s drug to treat adult patients with previously untreated mantle cell lymphoma has been recommended for European Union approval.
Drugs Health Pharma

AstraZeneca’s mantle cell cancer drug gets body’s nod for EU approval

HQ Team April 1, 2025: AstraZeneca’s drug to treat adult patients with previously untreated mantle cell lymphoma has been recommended for European Union.

Read More
AstraZeneca’s drug for treating limited-stage small cell lung cancer got a recommendation for approval from an EU regulator panel, according to the British-Swedish drugmaker.
Pharma

AstraZeneca to invest $2.5 Billion in Beijing R&D hub, expands China presence

HQ Team March 21, 2025: AstraZeneca has announced a $2.5 billion investment in a new Beijing R&D center, partnerships with Harbour BioMed and.

Read More
British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an end-stage trial, according to a joint statement.
Pharma

AstraZeneca acquires EsoBiotec for $1billion in a bid to push its cell therapy agenda

HQ Team March 17, 2025: AstraZeneca has announced plans to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies, for up to.

Read More
Eneboparatide (AZP-3601) meets its primary goal in the CALYPSO Phase III trial, offering hope for chronic hypoparathyroidism patients.
Drugs

Eneboparatide succeeds in Phase III trial for chronic hypoparathyroidism

HQ Team March 17, 2025: The Phase III CALYPSO trial, led by Alexion, AstraZeneca Rare Disease, has shown promising results for eneboparatide (AZP-3601),.

Read More
Eli Lilly has stopped trials of its investigational drug to treat chronic kidney disease for a “lack of foreseeable clinical benefit,” according to a company statement.
Drugs Health Medical

Eli Lilly halts trials of investigational chronic kidney disease drug

Eli Lilly has stopped trials of its investigational drug to treat chronic kidney disease for a “lack of foreseeable clinical benefit,” according to.

Read More
Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more than a year, according to a company statement.
Drugs Health Medical Pharma

J&J’s combination extends lives of cancer patients versus rival drug

Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more.

Read More
The European Union regulators have greenlighted AstraZeneca’s drug to treat an advanced form of non-small cell lung cancer after it reduced the death rate by 84%.
Drugs Medical Pharma

EU greenlights AstraZeneca’s non-small cell lung cancer drug

The European Union regulators have greenlighted AstraZeneca’s drug to treat an advanced form of non-small cell lung cancer after it reduced the death.

Read More
Merck & Co., Inc., announced it has met one of the primary goals during a late-stage trial of its breast cancer therapy, Keytruda.
Drugs Pharma

AstraZeneca, Merck announce promising results for breast cancer in trial 3

Bharti Jayshankar December 13, 2024: AstraZeneca and Merck have announced long-term results from the OlympiA Phase 3 trial, showing that Lynparza (olaparib) significantly.

Read More
The US regulator has granted a breakthrough therapy designation to British-Swedish AstraZeneca and Japan’s Daiichi Sankyo experimental drug for treating a certain type of lung cancer.
Drugs Medical Pharma

AstraZeneca, Daiichi’s trial drug for lung cancer, gets US regulator’s nod

The US regulator has granted a breakthrough therapy designation to British-Swedish AstraZeneca and Japan’s Daiichi Sankyo experimental drug for treating a certain type.

Read More
Twenty-four European universities have formed a network to impart skills to 10,000 medical students across undergraduate degree programmes to address current and future climate-related health threats, according to a  statement from the University of Glasgow.
Climate Health Pharma

European body to teach medical students health risks from climate change

Twenty-four European universities have formed a network to impart skills to 10,000 medical students across undergraduate degree programmes to address current and future.

Read More